Introduction {#sec1-1}
============

Chronic kidney disease (CKD) is an independent risk factor for gastrointestinal (GI) bleeding as it is associated with an increased risk of gastritis, peptic ulcer disease and angiodysplasia \[[@ref1]-[@ref5]\]. Patients with GI bleeding and comorbid CKD have worse outcomes than patients who have normal renal function \[[@ref2],[@ref6]\] and exhibit higher mortality than the general population (odds ratio \[OR\] 1.8, 95% confidence interval \[CI\] 1.7-1.9; P\<0.001 for CKD). The risk of mortality increases with disease progression to end-stage renal disease (ESRD) (OR 2.5, 95%CI 1.4-4.6; P=0.002) \[[@ref6]\].

Approximately 5-10% of patients overall present with obscure GI bleeding (OGIB) \[[@ref7]-[@ref9]\], defined as recurrent or persistent GI bleeding without an obvious etiology on esophagogastroduodenoscopy (EGD), colonoscopy, or radiographic imaging \[[@ref7]\]. The recent American College of Gastroenterology guidelines recommended reclassification of OGIB as small-bowel bleeding, as about 75% of OGIB originates in the small bowel \[[@ref7],[@ref10],[@ref11]\].

OGIB is a common dilemma for the gastroenterologist as it is commonly associated with an extensive diagnostic workup with limited yield. Management of this condition is more challenging in patients with CKD. Additionally, healthcare costs are higher in CKD patients with anemia compared to those without, in part because of a higher frequency of GI workup for bleeding \[[@ref12]\], higher rates of re-bleeding (OR 2.5, 95%CI 1.5-4.1; P\<0.001), higher rates of OGIB, increased transfusion requirements, and longer hospital stays \[[@ref6]\]. Given these challenges, the aim of this article was to review the evaluation and management of small-bowel and OGIB bleeding in patients with CKD. [Table 1](#T1){ref-type="table"} lists all identifiable studies on GI bleeding in this cohort of patients.

###### 

Studies on gastrointestinal bleeding in patients with chronic kidney disease

![](AnnGastroenterol-32-113-g001)

Anemia and GI bleeding in CKD {#sec1-2}
=============================

The prevalence of anemia in patients with CKD is twice that of the general population (15.4% vs. 7.6%), and increases with disease progression (8.4% in Stage 1 CKD vs. 53.4% in Stage 5 CKD) \[[@ref13]\]. This is due to a combination of anemia of chronic disease, erythropoietin deficiency and iron deficiency \[[@ref14]\].

A major component of iron deficiency anemia in these patients includes blood losses associated with routine hemodialysis (HD), particularly because of associated heparin infusions \[[@ref14]\]. However, they also have a higher prevalence of GI blood losses compared with the general population, largely attributed to uremic platelet dysfunction \[[@ref15],[@ref16]\]. Uremia causes impaired function of platelet glycoproteins GPIIb/IIIa, altered release of adenosine diphosphate and serotonin, and impaired prostaglandin and arachidonic acid metabolism, which together compromise platelet adhesion and aggregation \[[@ref17]\]. Given the increased platelet dysfunction that occurs with progressive CKD, GI bleeding is an expected complication seen in these patients \[[@ref18]\]. In one study, chromium-labeled red blood cells were used to evaluate the amount of GI blood loss in patients with CKD compared to patients with normal renal function. HD patients were found to have more occult GI blood losses (6.27 mL/day) compared with control patients (0.83 mL/day) and CKD patients not yet on HD (3.15 mL/day) \[[@ref19]\].

Patients with CKD have been reported to have higher rates of GI bleeding secondary to peptic ulcer disease and angiodysplasia compared with the general population. In a study evaluating anemic patients with non-dialysis dependent CKD stages 3-5, 52.9% were found to have sources of GI bleeding on upper and lower endoscopy. Gastric lesions were found more frequently in patients with stage 5 CKD compared to those with stages 3-4 CKD \[[@ref20]\].

Peptic ulcer disease is a common cause of upper gastrointestinal bleeding (UGIB) in patients with CKD. In a cohort study, investigators followed 796 patients who had just initiated HD for a 6-year period, along with 3184 age- and sex-matched patients without CKD, and compared rates of UGIB. The rate of UGIB was higher for the HD patients (hazard ratio \[HR\] 1.27, 95%CI 1.03-1.57). The most common etiology of this bleeding was peptic ulcer disease \[[@ref21]\]. Laeeq *et al* described the causes and characteristics of UGIB in ESRD patients and found that the most common findings were erosions (55.9%) and ulcers (30.3%). More than half (55.9%) of patients required therapeutic intervention \[[@ref22]\].

Although there is an increased incidence of peptic ulcer disease in CKD, this is often an easily identifiable and treatable cause of GI bleeding. However, angiodysplasia is typically the cause of small-bowel and recurrent bleeding and is more challenging to identify and manage. Even prior to the advances in small-bowel evaluation, patients with CKD were described as having a higher incidence of angiodysplasia of the stomach or proximal small bowel. One study evaluated the etiologies of UGIB in patients with CKD compared with the general population and found that the former had angiodysplasia as the most common source of bleeding (rate of 50% vs. 11%) \[[@ref3]\]. Another study evaluated 727 patients who underwent endoscopy for UGIB, 60 of whom had CKD. In this cohort, they found that the prevalence of angiodysplasia was higher in those with renal dysfunction overall and increased with the duration of comorbid CKD and need for hemodialysis \[[@ref23]\].

With the advent of video capsule endoscopy (VCE), one prospective study showed that patients with CKD were at higher risk (OR 4.5, 95%CI 1.9-10.6; P=0.0007) of having small-bowel angiodysplasia compared with the general population \[[@ref24]\]. CKD was also found to be an independent risk factor for small-bowel bleeding from vascular lesions \[[@ref5]\]. Lastly, another study evaluating patients who underwent capsule endoscopy noted a higher prevalence of vascular lesions in patients on HD (61.5% vs. 15.8%) \[[@ref25]\]. These studies suggest that not only do patients with CKD have a higher prevalence of angiodysplasia compared with the general population, but bleeding from angiodysplasia in this population is also the leading cause of recurrent bleeding \[[@ref3]\].

Endoscopic evaluation of OGIB {#sec1-3}
=============================

The literature on the utility of endoscopic evaluation in those with recurrent OGIB in ESRD patients is sparse. Typically, patients with recurrent GI bleeding of unidentifiable cause on upper and lower endoscopy are first evaluated with repeat upper or lower endoscopy based on the characteristics of the bleeding. If unrevealing, this should then be followed by small-bowel evaluation \[[@ref8]\].

Push enteroscopy (PE) {#sec2-1}
---------------------

In those presenting with recurrent melena or hematemesis, PE may be a better alternative than EGD for a second look, as it has a higher diagnostic yield with the addition of a limited small-bowel evaluation \[[@ref8],[@ref26]\]. It is particularly useful if proximal small-bowel lesions are suspected, as it has a higher yield in the proximal small bowel than VCE and allows for therapeutic intervention \[[@ref8]\]. A review of patients who underwent capsule endoscopy found that, of those with small-bowel angiodysplasia, 78.3% had lesions within the first 25% of small-bowel transit and 66.8% had lesions in the duodenum or at the ligament of Treitz, easily reached via PE \[[@ref27]\]. Another study investigated the distribution of angiodysplastic lesions in patients who presented with OGIB. Eighty percent of patients had angioectasias in the jejunum, 51% in the duodenum, and 22.8% in the stomach \[[@ref28]\]. However, of those with small-bowel bleeding secondary to non-vascular lesions, the yield of PE is suboptimal and capsule endoscopy was found to be superior \[[@ref8],[@ref29],[@ref30]\].

Given the yield of PE for vascular lesions, it may be a reasonable next step for evaluation of OGIB in CKD patients when there is high suspicion of an upper GI source. However, there are no studies examining the use of PE in OGIB in these patients.

VCE {#sec2-2}
---

If evaluation with PE is negative, the next step in evaluating OGIB is with VCE. However, if there is not high suspicion of a proximal small-bowel lesion, VCE would be a more appropriate first step in evaluating OGIB because it has a superior overall yield to PE, due to its ability to visualize the entire small bowel \[[@ref8],[@ref29]-[@ref31]\]. The overall diagnostic yield has been reported to range from 38-83% \[[@ref8]\]. A 2005 meta-analysis of 14 studies found that the diagnostic yield of capsule endoscopy was superior to that of PE (63% vs. 28%) for OGIB, and to that of small-bowel barium radiography (67% vs. 8%) for any finding when evaluating patients with OGIB. The number needed to test to find an additional clinically significant finding with capsule endoscopy over the other two modalities was 3 \[[@ref30]\].

VCE is most effective when done soon after the onset of bleeding. One study showed that capsule endoscopy had a markedly higher yield if it was performed within the first 15 days after the onset of overt GI bleeding rather than later (91% positive findings vs. 34%) \[[@ref32]\]. Another study by Pennazio *et al* found that the diagnostic yield of VCE was much higher in patients with ongoing overt bleeding than in those without active bleeding (92.3% vs. 12.9%). In those with prior episodes, the earlier the VCE was done after the cessation of bleeding, the higher the yield \[[@ref33]\]. Other factors associated with increased positive capsule endoscopy results included overt bleeding, use of non-steroidal anti-inflammatory drugs and a larger transfusion requirement \[[@ref34]\].

There is one study on the yield of capsule endoscopy in the evaluation of OGIB in patients with CKD. About half of the patients had positive VCE and 33.3% had angiodysplasia as the cause of bleeding. The overall yield was lower than in the general population, but the study itself was limited by the number of patients included \[[@ref35]\].

Device-assisted enteroscopy (DAE) {#sec2-3}
---------------------------------

DAE includes double-balloon (DBE), single-balloon (SBE) and through-the-scope balloon-assisted enteroscopy, and spiral enteroscopy (SE) \[[@ref36]\]. These techniques are used for extensive evaluation of the small bowel (with complete visualization in about 5-40% of patients) and allow for therapeutic intervention \[[@ref8],[@ref37]\].

Reported diagnostic yields for DAE are 60-80% for DBE \[[@ref8],[@ref38]-[@ref40]\], 33-74% for SBE \[[@ref8],[@ref41]-[@ref43]\], and 33-75% for SE \[[@ref44]-[@ref46]\]. The 2017 guidelines from the American Society of Gastrointestinal Endoscopy on the endoscopic evaluation of small-bowel bleeding suggest that all the DAE modalities have similar diagnostic and therapeutic outcomes \[[@ref9]\]. Timing of evaluation improves the yield of these modalities. A 2010 retrospective study found that the overall yield of DBE was higher if the examination was performed within a month of the most recent episode of bleeding (84% vs. 57%) \[[@ref47]\]. VCE and device-assisted enteroscopy have similar diagnostic yields and are typically considered complementary modalities \[[@ref8],[@ref48],[@ref49]\]. There are no studies on the use of DAE in evaluating OGIB in those with comorbid CKD.

Recurrent bleeding following negative endoscopic evaluation {#sec2-4}
-----------------------------------------------------------

It is not uncommon for patients with OGIB and negative small-bowel evaluation to present with recurrent bleeding, particularly patients with CKD. One study by Curdia Goncalves *et al* followed 68 patients with OGIB and negative VCE for 32 months. Re-bleeding occurred in 23.5% of patients at an average of 15 months following the initial presentation \[[@ref50]\]. Shinozaki *et al* followed 42 patients with overt OGIB and negative DBE to evaluate rates of re-bleeding. Re-bleeding occurred in 38% of patients at a mean follow up of 54 years \[[@ref51]\].

Another retrospective study evaluated the rate of recurrent OGIB after a negative VCE. Re-bleeding occurred in 27.4% of patients at an average of 15 months from the initial presentation; 22.6% of the patients who suffered re-bleeding had confirmed angiodysplasia. Factors associated with re-bleeding included age \>65 years, CKD, aortic stenosis, anticoagulant use and overt bleeding. Patients with CKD had an increased risk of re-bleeding on univariate analysis (HR 3.498, 95%CI 1.265-9.671; P=0.016) \[[@ref52]\].

Yield of repeat endoscopy {#sec2-5}
-------------------------

In the setting of recurrent bleeding, the data on repeat small-bowel evaluation are limited and conflicting. In the study by Curdia Goncalves *et al*, 57.4% of patients who re-bled underwent further diagnostic testing and a cause of bleeding was only found 13% of the time \[[@ref50]\]. Conversely, another study demonstrated a high yield of repeat VCE. Of those with negative prior VCE, 75% had findings on repeat VCE and 62.5% of these patients had a change in management \[[@ref53]\].

In a study by Shinozaki *et al* that included patients with initial negative DBE, of those patients who re-bled, 88% underwent further diagnostic evaluation with a yield of 71%, and of those with a confirmed source, 70% were in the small bowel \[[@ref51]\]. In another study that looked at the yield of repeat DBE for recurrent OGIB, 53.1% of patients had positive findings and of these 94.1% were angiodysplasia. All identified bleeding lesions were managed with argon plasma coagulation. However, the yield of repeat DBE for recurrent bleeding was only high in those with previously positive DBE. Those with initially negative DBE had negative evaluations the second time \[[@ref54]\]. There are no studies on the yield of repeat endoscopy for recurrent OGIB in patients with CKD.

Radiologic evaluation {#sec1-4}
---------------------

Radiographic modalities also play a role in the work up of OGIB, but in general have more utility in the setting of overt bleeding. In those with ongoing bleeding and hemodynamic stability, computed tomography angiography (CTA) and scintigraphy may be useful in identifying the site of bleeding and allowing for targeted intervention. Patients with brisk bleeding are best evaluated with CTA. A meta-analysis of the use of CTA in those presenting with acute GI bleeding showed an overall sensitivity of 89% and a specificity of 85% \[[@ref55]\]. Patients with positive CTA are also more likely to have positive findings on enteroscopy \[[@ref56]\]. Given the risk of contrast nephropathy, CTA has traditionally had a limited role in evaluation of OGIB in CKD and has not been well studied.

Patients with slower rates of bleeding can be better evaluated with scintigraphy, particularly if a patient presents later after the onset of bleeding \[[@ref8]\]. The overall diagnostic yield varies among reports in the literature (45-73%) \[[@ref57]-[@ref61]\]. One prospective study assessed the use of scintigraphy in the evaluation of obscure overt bleeding and found an overall yield of 65% with a localization accuracy of 75% \[[@ref61]\]. Another study evaluated the utility of scintigraphy in localizing bleeding from angiodysplasia in patients with comorbid CKD compared with colonoscopy and found that scintigraphy had a much higher sensitivity (88.9% vs. 30%) \[[@ref62]\]. Scintigraphy is limited by its ability to characterize the source of bleeding and variable accuracy due to the potential for false localization of bleeding with rapid transit of labeled red blood cells through the small-bowel lumen \[[@ref8],[@ref57],[@ref60],[@ref61],[@ref63],[@ref64]\].

Diagnostic angiography is typically reserved for the hemodynamically unstable, particularly those with large transfusion requirements and who present early after the onset of bleeding, as the yield is highest in this setting \[[@ref8],[@ref65]-[@ref68]\]. The benefit of this approach is its therapeutic potential. It is otherwise not used often for diagnosis because of its invasive nature and associated risks \[[@ref8]\]. The overall yield of conventional angiography ranges between 20-51% \[[@ref66],[@ref69]-[@ref71]\]. Despite the utility of angiography in diagnosing the cause of OGIB, VCE remains superior and has a higher diagnostic yield \[[@ref69]\]. As it poses similar risks to those associated with CTA, contrast exposure limits the role of angiography in evaluating OGIB in patients with CKD.

In addition to concerns regarding contrast exposure, patients who present with recurrent bleeding are more likely to get multiple radiographic scans with increased radiation exposure. One study evaluated the cancer risk associated with each CTA and found that abdominal CTAs specifically confer the highest cancer risk, estimated to be around 36 cancer risks per 1 million procedures \[[@ref72]\].

CT or magnetic resonance enterography (CTE or MRE) can be used as part of the workup of OGIB. However, in regard to bleeding specifically from vascular lesions and angiodysplasia, VCE has superior yield and higher sensitivity in identifying these lesions \[[@ref73]-[@ref77]\]. Thus, CTE or MRE have little utility as part of the initial work up of OGIB in patients with CKD.

Endoscopic intervention {#sec1-5}
=======================

Specific interventions once a culprit lesion is found depends on the type of lesion itself. While it can be treated with electrocautery, angiodysplasia is primarily treated with argon plasma coagulation (APC) via PE or DAE. Other methods of hemostasis include injection therapy or mechanical hemostasis with clips. As mentioned above, DAE is reserved largely for these therapeutic interventions \[[@ref9]\].

The data regarding long-term outcomes are controversial. However, the majority of studies report no difference in long-term outcomes in those treated with endoscopy vs. observation alone \[[@ref78],[@ref79]\]. One systematic review looked at the long-term outcomes of patients with bleeding from angiodysplasia managed with endoscopic therapy versus observation. Re-bleeding rates in the two groups were 42.7% and 49.2% \[[@ref78]\]. Another systematic review found that the pooled re-bleeding rate of small-bowel angiodysplasia following endoscopic intervention was 45% \[[@ref80]\]. A 2013 study reviewed patients who underwent DAE for small-bowel bleeding from angiodysplasia. The overall diagnostic yield was 74% and the therapeutic yield 67%; however, there was no difference in long-term outcomes between those patients who received endoscopic therapy and those who underwent observation alone: re-bleeding occurred in 30% of the former and 20% of the latter \[[@ref81]\]. A 2012 retrospective study evaluated re-bleeding rates in patients with OGIB who received endoscopic therapy (primarily APC) for small-bowel vascular lesions. The re-bleeding rate was 46% at 36-month follow up \[[@ref82]\]. A 2009 survey study evaluated the long-term outcomes of 101 patients following DBE for OGIB. Of those followed, 40 had angiodysplasia treated with APC; of these 40 patients, 54% had re-bleeding or recurrent need for iron replacement and blood transfusions \[[@ref83]\]. A 1996 study evaluated patients with OGIB who underwent PE. Less than half of patients treated with electrocautery for angiodysplasia had a good outcome, defined as not having recurrent anemia or blood transfusion requirements \[[@ref84]\]. Lastly, a 1987 study compared the long-term outcomes of those with angiodysplasia treated either with surgical resection, endoscopic electrocautery or transfusion alone. No modality was statistically superior in treating and preventing recurrent bleeding \[[@ref85]\].

Conversely, a few studies showed effective reduction of bleeding with endoscopic therapy. A 1996 study retrospectively evaluated the long-term follow up of 83 patients found to have small-bowel angiodysplasia on PE. Of these patients, 55 underwent electrocautery and 28 did not, with a mean follow up of 30 months for the former and 26 months for the later. The patients treated with electrocautery had a statistically significant reduction in recurrent bleeding and blood transfusions \[[@ref86]\]. Similarly, a prospective 2006 study evaluated long-term follow up in 100 patients who underwent argon plasma ablation therapy for colonic angiodysplasia: 85% had stabilized hemoglobin concentration without recurrence of overt bleeding after a 20-month follow up \[[@ref87]\]. Lastly, a 2012 prospective study evaluated the long-term outcomes of 61 patients following SE, of whom 45 underwent endoscopic therapy. There was a statistically significant reduction in the rate of overt bleeding, transfusion requirements, mean hemoglobin and need for iron supplementation over an average of 25.3-month follow up \[[@ref88]\]. There are no studies on endoscopic intervention for OGIB in patients with CKD.

Non-endoscopic management of GI bleeding {#sec1-6}
========================================

Considering the low efficacy of endoscopic management in the long-term prevention of recurrent bleeding from angiodysplasia, it is important to consider non-endoscopic therapies.

Transfusions and iron replacement therapy {#sec2-6}
-----------------------------------------

As discussed above, observation alone with as-needed transfusions and iron replacement for anemia are non-inferior to endoscopic management. This is potentially a viable option for those for whom sedation presents a high risk, or have had multiple prior endoscopic interventions with recurrent or persistent bleeding. It is important to note, however, that oral iron is virtually ineffective at replenishing iron stores in those with deficiency and comorbid CKD. It is thought that uremia prevents the GI absorption of iron \[[@ref14]\].

A prospective study compared placebo with oral and intravenous (IV) iron replacement in patients with iron deficiency anemia on HD. Both oral iron and placebo were ineffective in improving the patients' hemoglobin levels, but IV iron was efficacious (with an average rise in hemoglobin from below 7 g/dL to above 12 g/dL) \[[@ref89]\]. The second study was a randomized control trial of patients iron replete on HD who were initiating erythropoietin for hemoglobin levels less than 8.5 g/dL. Patients were randomized to placebo, oral iron supplementation or IV iron supplementation. Those on IV iron had larger improvements in their hemoglobin concentrations and were the only group able to maintain ferritin stores. The other two groups had a drop in their ferritin levels over time \[[@ref90]\].

Somatostatin analogs {#sec2-7}
--------------------

Increasingly, studies have shown that octreotide is an effective option for the management of bleeding from angiodysplasia and should be strongly considered in those with recurrent bleeding despite endoscopic intervention \[[@ref91]\]. Octreotide is a somatostatin analog whose reported mechanism of action includes decreasing splanchnic blood flow, inhibiting angiogenesis, improving platelet aggregation and increasing vascular resistance \[[@ref79],[@ref80],[@ref92]\].

A review by Jackson and Gerson found that somatostatin analogs were effective in reducing recurrent bleeding episodes and transfusion requirements with a pooled OR of 14.5 (95%CI 5.9-36) \[[@ref80]\]. A 2010 meta-analysis of studies reporting the use of somatostatin analogs in the treatment of angiodysplasia determined a clinical response of 76%, with a weighted mean difference in transfusion requirements before and after treatment of −2.2 (95%CI −3.9 to −0.5) \[[@ref93]\]. Another study followed patients with recurrent GI bleeding secondary to angiodysplasia after at least 6 months of treatment with a somatostatin analog. Following treatment, the rate of bleeding episodes was reduced from 73% to 20%, the number of transfusions needed dropped from a median of 10 to 2, and the mean hemoglobin increased from a median of 7 to 10 g/dL \[[@ref94]\]. Similarly, a prospective study evaluated the efficacy of 1-year octreotide treatment in patients with chronic bleeding secondary to angiodysplasia. Complete response without the need for transfusion or iron supplementation was achieved in 69% of patients, a partial response in 8% of patients and no response in 23% of patients \[[@ref95]\].

A 2017 study evaluated the use of combination endoscopic therapy and the somatostatin analog lanreotide compared to endoscopic therapy alone in patients with refractory iron deficiency anemia secondary to small-bowel angioectasia. Combination therapy led to statistically significant reduction in transfusion requirements and bleeding episodes with an increase in hemoglobin compared with the other group \[[@ref96]\].

One case series reported 3 patients with CKD and recurrent bleeding secondary to diffuse GI angiodysplasia that responded to 6 months of octreotide therapy \[[@ref97]\]. However, no formal studies have examined the efficacy of octreotide in treating angiodysplasia in patients with comorbid CKD.

Thalidomide {#sec2-8}
-----------

Thalidomide is the most recent addition to the medical armamentarium in treating bleeding from angiodysplasia. Its proposed mechanism of action is related to anti-angiogenic effects at low doses, as the development of angiodysplasia is suspected to be related to elevated levels of vascular endothelial growth factor causing increased angiogenesis \[[@ref80],[@ref92],[@ref98],[@ref99]\].

A 2011 randomized control trial revealed that thalidomide was effective in reducing the rates of re-bleeding in patients with recurrent bleeding from angiodysplasia. Patients were randomized to treatment or control (treated with iron therapy) groups and were followed for at least 1 year. Effective response was defined as a 50% reduction in bleeding episodes. Those treated with thalidomide had a response rate of 71.4%, compared with 3.7% for the control group. Those treated with thalidomide also had lower transfusion requirements and fewer hospitalizations. Side effects experienced by patients included neuropathy and somnolence \[[@ref100]\]. A 2012 prospective study evaluated patients treated with thalidomide for 4 months for refractory bleeding secondary to angiodysplasia. Prior to treatment, the average hemoglobin was 6.5 g/dL, which increased to 11.3 g/dL at 2 months and 12.1 g/dL at 4 months of treatment. However, 16.7% of patients had to stop treatment early because of side effects \[[@ref101]\]. One case report described effective treatment of refractory GI bleeding secondary to diffuse angiodysplasia in a patient on HD. The patient had a significant reduction in transfusion requirements and number of angiodysplastic lesions found on endoscopy \[[@ref102]\].

Desmopressin {#sec2-9}
------------

Given that bleeding in patients with CKD is related to uremic platelet dysfunction, desmopressin can potentially be used as a short-term reversal agent for this acquired coagulopathy in the management of patients presenting with overt or ongoing bleeding \[[@ref4],[@ref18],[@ref103],[@ref104]\]. However, only limited relevant data are available.

Intranasal or IV desmopressin lasts about 8 h and can be used for up to two total doses before exhibiting tachyphylaxis \[[@ref4]\]. The effect of desmopressin peaks at 1-2 h \[[@ref103]\]. A double-blind crossover study compared the effect of desmopressin to placebo on bleeding times in patients on HD. Those that received desmopressin had a reduction in bleeding time from an average of 21.3±8 min to 11.5±6 min; however, there was no change in hemoglobin or platelet count \[[@ref105]\].

The proposed mechanism of action is multifactorial and includes an increased number of von Willebrand Factor (vWF) and Factor VIII (FVIII) complexes, likely via increased release from storage sites, improved platelet membrane receptor binding of the vWF: FVIII complexes \[[@ref103]\], and direct action on the platelet membrane leading to increased platelet serotonin uptake and subsequent adenosine triphosphate release \[[@ref105], [@ref106]\].

It is important to note that the effect of desmopressin on transfusion requirements in those with active bleeding and its clinical utility in preventing GI bleeding have not been studied. Additionally, the same effect of desmopressin in reducing platelet dysfunction is also achieved by HD \[[@ref18],[@ref107]\]. There is reported utility prior to surgical procedures in preventing bleeding, and it may prove to be useful in patients who are about to undergo endoscopic therapy.

Hormonal therapy {#sec2-10}
----------------

In the 1980s and 90s, hormonal therapy gained traction in the prevention of GI bleeding \[[@ref108]\]. However, more recent studies have proven it to be ineffective, particularly in the setting of bleeding from angiodysplasia \[[@ref9],[@ref80]\]. Data on the effect of hormonal therapy in preventing bleeding in those with CKD are controversial and overall lacking \[[@ref109]\].

A systematic review by Jackson and Gerson of the management of GI bleeding secondary to angiodysplasia found that hormonal therapy was ineffective overall (OR 1.0, 95%CI 0.5-1.96) \[[@ref80]\]. A multicenter randomized controlled trial enrolled patients with small-bowel angiodysplasia into a treatment or control group and found that there was no significant difference between the two groups with regard to the number of bleeding episodes and transfusion requirements \[[@ref110]\]. Another cohort study evaluated patients with small-bowel angiodysplasia and found no difference in transfusion requirements between those receiving hormonal therapy versus observation alone \[[@ref111]\].

Regarding patients with CKD specifically, there are insufficient data on the use of hormonal therapy to prevent bleeding. The above randomized controlled trial was not sufficiently powered to exclude a benefit in patients with CKD \[[@ref109],[@ref110]\], in whom it has been shown that hormonal therapy can reduce bleeding times \[[@ref112]-[@ref114]\]. There are case series and case reports suggesting that hormonal therapy has been effective in the management of bleeding from angiodysplasia in patients with CKD \[[@ref115]-[@ref118]\]. Given that the data for the general population show no benefit from using hormonal therapy, until there are studies proving otherwise in the CKD population we would avoid using it in this setting.

Arterial embolization {#sec2-11}
---------------------

With advances in technology allowing for super-selective mesenteric embolization, the overall risks of embolization---particularly bowel infarction---have decreased with time. However, most data regarding arterial embolization for GI bleeding are from patients with bleeding sources outside of the small bowel \[[@ref119]-[@ref122]\]. Reported clinical success rates range between 63% and 71.4%, with mortality ranging between 9% and 19.3% \[[@ref119],[@ref121],[@ref123]\]. There are no studies on the role of arterial embolization in managing OGIB in patients with CKD.

Surgical treatment {#sec2-12}
------------------

Surgery is typically reserved for refractory and life-threatening cases of bleeding. The primary surgical intervention is intraoperative enteroscopy with subsequent surgical resection or endoscopic therapy \[[@ref80]\]. Surgery is also useful in the lysis of adhesions that would otherwise preclude the employment of advanced endoscopic procedures \[[@ref9]\].

Given the high negative predictive value of endoscopic modalities for small-bowel evaluation, there is little to no utility for intraoperative enteroscopy in diagnosis. It is primarily reserved for patients who have a lesion identified by other endoscopic techniques and need further localization during surgery prior to an intervention \[[@ref124],[@ref125]\].

Concluding remarks {#sec1-7}
==================

While peptic ulcer disease is common in CKD, angiodysplasias are the most common culprit of OGIB in patients with CKD. These patients frequently present with recurrent or OGIB despite endoscopic evaluation and intervention. The available evidence concerning the management of patients with OGIB is ambiguous and systematic reviews suggest no overall difference in outcomes between those who undergo endoscopic versus conservative management for these lesions. Therefore, it is important to weigh the risks and the benefits prior to endoscopic intervention, especially in patients with significant comorbidities. We propose an algorithmic approach to evaluating obscure GI bleeding in patients with CKD based on existing guidelines in [Figure 1](#F1){ref-type="fig"}. There are minimal data on the endoscopic evaluation, intervention and outcomes of OGIB specifically in patients with CKD, and more studies are necessary to assess whether their outcomes compare to those in the general population.

![Above is a recommended diagnostic algorithm for obscure gastrointestinal bleeding in patients with chronic kidney disease. Adapted from "ACG Clinical Guideline: Diagnosis and Management of Small Bowel Bleeding" \[[@ref8]\] and "Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline" \[[@ref31]\]\
*EGD, esophagogastroduodenoscopy; CT, computed tomography*.](AnnGastroenterol-32-113-g002){#F1}
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